Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 2/20 | 0.33 |
| ▸ | CTSD | P07339 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.32 |
| ▸ | CCR5 | P51681 | 2/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.30 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4484836 | 0.90 | LMNA (0.37) | LMNABACE1CTSDGAAPKM | |
| SCHEMBL4484289 | 0.87 | MEN1 (0.31) | — | |
| SCHEMBL4474453 | 0.74 | LMNA (0.32) | LMNA | |
| SCHEMBL4462425 | 0.71 | — | — | |
| SCHEMBL4467966 | 0.65 | — | — | |
| SCHEMBL28959276 | 0.63 | EZH2 (0.43) | LMNABACE1GAAPKMSIGMAR1 | |
| SCHEMBL26664150 | 0.63 | ALDH1A1 (0.49) | GAASIGMAR1 | |
| SCHEMBL19917508 | 0.62 | ALDH1A1 (0.47) | LMNA | |
| SCHEMBL19917466 | 0.62 | ALDH1A1 (0.47) | LMNA | |
| SCHEMBL4468597 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576094-B2 | Spiro derivatives as lipoxygenase inhibitors | ELI LILLY AND COMPANY (US) | 2009-08-18 | — | — | US | disclosed |
| US-20060128790-A1 | Spiro derivatives as lipoxygenase inhibitors | GALILEO PHARMACEUTICALS, INC. | 2006-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128790-A1 | Spiro derivatives as lipoxygenase inhibitors | ALOX15B, ALOX5, ALOX15 | LMNA 1769/4885BACE1 4231/4885CTSD 2488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.